Clinical trial

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

NCT03667820

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Osimertinib Normalized identity: osimertinibView linked drug · Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention SABR Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-09-26

PhasePHASE2

Conditions

Non-small Cell Lung Cancer (NSCLC)unresolved

Interventions

OsimertinibDRUG · verified · RxNorm: osimertinib

SABRRADIATION

Sponsors & collaborators

University of Texas Southwestern Medical Centerlead sponsor

AstraZenecacollaborator

Mapped research locations

DallasTexas, United States1 DuarteCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03667820 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.